Jessica Gray, MD
Family Medicine · Lubbock, TXNPI 1851785000
Payments from drug & device makers
Across 312 payments — averaging $49.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organon$10K
- AbbVie$782
- Lilly USA, LLC$659
- Pfizer$628
- Abbott$468
- GSK$408
- plus $2K from 31 others
What the payments were for
- Speaking & faculty fees$9,91765%
- Travel & lodging$3182%
- Food & beverage$4,99533%
- Education$1001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organon | 19 | $10,452 |
| AbbVie(2 entities) | 44 | $782 |
| Lilly USA, LLC | 58 | $659 |
| Pfizer | 39 | $628 |
| Abbott | 29 | $468 |
| GSK | 23 | $408 |
| Astellas Pharma US Inc | 10 | $307 |
| Novo Nordisk | 13 | $203 |
| AstraZeneca | 10 | $202 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $168 |
| Biohaven Pharmaceutical Holding Company Ltd. | 12 | $157 |
| Amgen | 9 | $130 |
| Axsome Therapeutics, Inc. | 3 | $76 |
| Arbor Pharmaceuticals, Inc. | 5 | $74 |
| Boston Scientific | 2 | $68 |
| Inspire Medical Systems, Inc. | 1 | $48 |
| Ultragenyx Pharmaceutical Inc. | 3 | $41 |
| Novartis | 2 | $39 |
| Dexcom, Inc. | 2 | $37 |
| Lundbeck LLC | 2 | $35 |
| Medtronic | 2 | $34 |
| Vanda Pharmaceuticals Inc. | 1 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Amarin Pharma, Inc. | 2 | $24 |
| Supernus Pharmaceuticals, Inc. | 1 | $24 |
| Aytu Biopharma, Inc. | 1 | $23 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Bayer | 1 | $19 |
| Si-bone, Inc. | 1 | $18 |
| Boehringer Ingelheim | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Mayne Pharma Commercial LLC | 1 | $16 |
| Seqirus USA Inc | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Avion Pharmaceuticals | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEXPLANON$10,235
How this compares
$15,330 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 56 | $58,834 |
| JardianceEmpagliflozin | 42 | $48,472 |
| OzempicSemaglutide | 44 | $41,464 |
| EliquisApixaban | 24 | $25,581 |
| ProliaDenosumab | 14 | $23,339 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $22,045 |
| TrulicityDulaglutide | 19 | $19,929 |
| RybelsusSemaglutide | 12 | $11,433 |
| FarxigaDapagliflozin Propanediol | 12 | $11,412 |
| Emgality PenGalcanezumab-Gnlm | 11 | $7,771 |
| Levothyroxine Sodium | 309 | $4,148 |
| Atorvastatin Calcium | 245 | $2,456 |
| Raloxifene Hcl | 26 | $1,562 |
| Rosuvastatin Calcium | 141 | $1,489 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 55 | $1,471 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $659 | $78,76475 claims |
| Novo NordiskOzempic, Rybelsus | $203 | $52,89756 claims |
| Boehringer IngelheimJardiance | $18 | $48,47242 claims |
| PfizerEliquis | $628 | $25,58124 claims |
| AmgenProlia | $130 | $23,33914 claims |
| GSKTrelegy Ellipta | $408 | $22,04532 claims |
| AstraZenecaFarxiga | $202 | $11,41212 claims |
| AbbVieSynthroid | $782 | $1,25626 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Lubbock
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.